Toni H. Choueiri und Dana-Farber Cancer Institute - Info zur Person

(1 - 29 von 37

)

Nivolumab und Cabozantinib: Zwei neue Wirkstoffe bei ...

www.aerzteblatt.de

Sep 28, · Cabozantinib konnte anders als Nivolumab das progressionsfreie Überleben von 3,8 auf 7,4 Monate verlängern, wie Toni Choueiri vom Dana-Farber Cancer Institute aus Boston und Mitarbeiter im …

Ipsen Announces Data Presentations of Cabozantinib (Cabometyx),...

www.finanznachrichten.de

Dr. Toni Choueiri, Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA Session: Presidential session 3 Oral presentation Monday, October

Coronavirus study: Cancer treatment not major COVID-19 risk ...www.usatoday.com › story › news › health ›

eu.usatoday.com

... may face, and to help guide treatment, said co-author Toni Choueiri, a genitourinary oncologist at the Dana-Farber Cancer Institute in Boston.

How kidney cancer affects the risks of coronavirus - Kidney ...www.kidneycancer.org › stories

www.kidneycancer.org

Toni Choueiri, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute/Brigham and Women's Hospital in Boston, ...

Exelixis Provides Update on Timing of Key Cabozantinib Clinical Data...

www.businesswire.com

Dr. Toni Choueiri, Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Session: Presidential Symposium 3, Monday, October 10, – 16:30-18:10 CEST, Copenhagen room. Note: This is a National Cancer Institute Cancer Therapy Evaluation ...

Dr. Toni Choueiri, Medical Oncologist in Boston, MA | US ...

health.usnews.com

Dr. Toni Choueiri is a Medical Oncologist in Boston, MA. Dr. Choueiri admits patients at Dana-Farber Cancer Institute, Boston Children's Hospital, Brigham and ...

Toni Choueiri, MD | Authors | Targeted Oncology ...www.targetedonc.com › authors

www.targetedonc.com

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, at Dana-Farber Cancer Institute, and ...

Choueiri, Toni | SAGE Publications Inc

us.sagepub.com

Toni Choueiri Dana-Farber Cancer Institute, Boston, MA, USA. Browse · Books · Journals · Digital Library Products · Digital Solutions for your Course · Catalogs.

Dr Toni Choueiri discusses a new Phase 2 clinical trial on volitinib in ...www.oncologytube.com › video

oncologytube.com

At the Thirteenth International Kidney Cancer Symposium, Dr Toni Choueiri (Dana-Farber Cancer Institute and Harvard Medical School, MA) discusses the new ...

Wikipedia: Toni Choueiri - Wikipedia

Toni K. Choueiri is a Lebanese American medical oncologist and researcher. He is the Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School and Director of the Lank Center for Genitourinary Oncology at the Dana–Farber Cancer Institute. His work has led to the establishment of several novel drugs (cabozantinib, avelumab ...

‪Toni Choueiri‬ - ‪Google Scholar‬

scholar.google.ca

‪Dana-Farber Cancer Institute‬ - ‪‪Cited by ‬‬ - ‪Genitourinary Oncology‬

Toni Choueiri, MD - Dana-Farber Cancer Institute | Boston, MA

www.dana-farber.org

Dr. Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. He is the Medical Director, International ...

Dr. Toni Choueiri on Cabozantinib Versus Everolimus in Renal Cell...

www.onclive.com

Toni Choueiri, MD, Clinical Director, Lank Center for Genitourinary Oncology Director, Kidney Cancer Center, Senior Physician at Dana-Farber Cancer Institute, discusses the results of the METEOR trial in advanced renal cell carcinoma (RCC).

Toni Choueiri, MD Dana-Farber Cancer Institute

providers.youhaveus.org

Dr. Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI)/Brigham and Women's Hospital ...

Does cabozantinib have potential to become a first-line treatment for...

medonline.at

Dr Toni Choueiri, Director, Kidney Cancer Center, Dana-Farber Cancer Institute, Boston, US The CABOzantinib versus SUNitinib (CABOSUN) study was conducted by the Alliance for Clinical Trials in Oncology, part of Exelixis’ collaboration with the National Cancer Institute (NCI) Cancer Therapy Evaluation Program.

Exelixis Completes Enrollment of the METEOR Phase

pipelinereview.com

“METEOR was designed to evaluate cabozantinib’s potential as a treatment for metastatic renal cell carcinoma, an aggressive form of the disease that is usually incurable,” said Toni Choueiri, MD, clinical director of the Lank Center for Genitourinary Oncology and director of the kidney cancer center, Dana-Farber Cancer Institute.

Laurence Albiges and Toni Choueiri on Metastatic RCC Perspectives on...

ascopost.com

▶Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of Gustave Roussy ...

Toni Choueiri and Lauren Harshman on the PROSPER Trial - The ASCO Post

ascopost.com

▶Toni K. Choueiri, MD, and Lauren C. Harshman, MD, both of Dana-Farber Cancer Institute, discuss phase III ...

Toni Choueiri and Jonathan Rosenberg Bladder Cancer Roundup - The...

ascopost.com

▶Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Jonathan E. Rosenberg, MD, of Memorial Sloan ...

Toni K. Choueiri, MD, on Papillary RCC: Phase II Trial Results - The...

www.ascopost.com

▶ 2:54Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses a single-arm biomarker-based study of ...

2020 Kidney Cancer Highlight - Harnessing Predictive ...cdmrp.army.mil › KCRP › researc...

cdmrp.health.mil

John Ebos, Ph.D., Roswell Park Comprehensive Cancer Center, and Toni Choueiri, M.D., Dana-Farber Cancer Institute, Harvard Medical ...

Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell...

clinicaltrials.gov

Information provided by (Responsible Party): Toni Choueiri, MD, Dana-Farber Cancer Institute. ClinicalTrials.gov Identifier: NCT

Genetic Predictors of Response to mTOR inhibitors in advanced Renal...

grantome.com

See 3 grants from Toni Choueiri · See 110 grants from David Kwiatkowski · See grants from Dana-Farber Cancer Institute. Share this grant: LinkedIn : Facebook ...

Study of Atezolizumab + Bevacizumab in Patients With Advanced...

clinicaltrials.gov

Genentech, Inc. Information provided by (Responsible Party):. Toni Choueiri, MD, Dana-Farber Cancer Institute. Study Details ...

Dose-Dense MVAC With Pegfilgrastim Support in Subjects With...

clinicaltrials.gov

Toni Choueiri, MD, Dana-Farber Cancer Institute. ClinicalTrials.gov Identifier: NCT First received: December 15, Last updated: June 3,

How having cancer can put Covid-19 patients at higher risk of ...kvia.com › health ›

kvia.com

Toni Choueiri, of the Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School in Boston, who worked on the Lancet ...

Exelixis drug better than everolimus in metastatic renal-cell...

healthylivingmagazine.us

... to everolimus in the randomized open-label test, chief author Dr. Toni Choueiri of the Dana-Farber Cancer Institute in Boston told Reuters Health by phone.

Pittsfield's Shaun Tierney to again be Walk Hero at Jimmy Fund Walk |...

www.berkshireeagle.com

PITTSFIELD — Since 1989, the Jimmy Fund Walk has been dedicated to supporting patient care and cancer research at Dana-Farber Cancer Institute.On September 24,...

Clinical Treatment Decisions for Advanced Renal Cell Cancer in:...

jnccn.org

Toni K. Choueiri, MD. + Author Affiliations. Presented by Toni K. Choueiri, MD, Head of the Kidney Cancer Center at Dana-Farber Cancer Institute, Boston, ...

Alle Infos zum Namen "Toni H. Choueiri"

Verwandte Suchanfragen zu Toni H. Choueiri

Dana Farber

Personen
Vorname "Toni" (11215)
Name "Choueiri" (39)

sortiert nach Relevanz / Datum

Erweiterte Suche

Person-Suchen: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Toni H. Choueiri und Dana-Farber Cancer Institute Person-Info